Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Lennon RP, Miller EL, Snyder B, Van Scoy LJ. Self-reported influenza and influenza-like symptoms in U.S. adults age 18-64 between September 1, 2019 and April 15, 2020. J Clin VIrol. 2021 Jan;134:104709. doi: 10.1016/j.jcv.2020.104709
Arvelo W, Sosa SM, Juliao P, Lopez MR, Estevez A, Lopez B, Morales-Betoulle ME, Gonzalez M, Gregoricus NA, Hall AJ, Vinje J, Parashar U, Lindblade KA. Norovirus outbreak of probable waterborne transmission with high attack rate in a Guatemalan resort. J Clin VIrol. 2012 Sep;55(1):8-11. doi: 10.1016/j.jcv.2012.02.018
Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease evidence from a United States managed care population. Hum Vacci. 2011 Apr 1;7(4):458-65.
Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vacci. 2011 Jan 1;7(1):96-101.